You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Evolving Best Practices for Managing AL Amyloidosis: Sharing Perspectives

  • Authors: Giovanni Palladini, MD, PhD​; Marianna Fontana, MD, PhD; Efstathios Kastritis, MD; Nelson Leung, MD
  • CPD Released: 2/1/2022
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 2/1/2023
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of hematologists/oncologists, cardiologists, and nephrologists outside of the United States.

The goal of this activity is to improve physicians' understanding of amyloid light chain (AL) amyloidosis and their ability to optimally care for these patients as part of the multidisciplinary team.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Risk assessment for the development of AL amyloidosis
    • Clinical trial data supporting novel treatment strategies for AL amyloidosis
  • Have greater competence related to
    • Selecting therapy for patients with AL amyloidosis
  • Demonstrate greater confidence in their ability to
    • Optimize care for patients with AL amyloidosis within the multidisciplinary team


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Giovanni Palladini, MD, PhD

    Director, Amyloidosis Research and Treatment Center
    Fondazione IRCCS Policlinico San Matteo
    Department of Molecular Medicine
    University of Pavia
    Pavia, Italy

    Disclosures

    Disclosure: Giovanni Palladini, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Janssen
    Other: Honoraria from: Janssen; Pfizer Inc.; Siemens

  • Marianna Fontana, MD, PhD

    Professor of Cardiology
    Hon Consultant Cardiologist
    UCL Cardiac CMR Service, UCL (Royal Free Campus)
    National Amyloidosis Centre
    London, United Kingdom

    Disclosures

    Disclosure: Marianna Fontana, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Alnylam Pharmaceuticals, Inc.; Attralus; Intellia; Ionis Pharmaceuticals; Novo Nordisk; Pfizer Inc.
    Grants for clinical research from: Eidos; Pfizer Inc.

  • Efstathios Kastritis, MD

    Professor of Clinical Therapeutics-Medical Oncology
    Department of Clinical Therapeutics
    National and Kapodistrian University of Athens School of Medicine
    Athens, Greece

    Disclosures

    Disclosure: Efstathios Kastritis, MD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; Genesis; Janssen; Pfizer Inc.; Prothena; Takeda
    Speaker or a member of a speakers bureau for: Amgen; Genesis; Janssen; Pfizer Inc.; Prothena; Takeda
    Grants for clinical research from: Amgen; Janssen; Pfizer Inc.

  • Nelson Leung, MD

    Professor of Medicine
    Division of Nephrology
    Hematology, Department of Laboratory Medicine and Pathology
    Mayo Clinic
    Rochester, Minnesota, United States

    Disclosures

    Disclosure: Nelson Leung, MD, has the following relevant financial relationships:
    Advisor or consultant for: AbbVie, Inc.
    Grants for clinical research from: Alynlam Pharmaceuticals, Inc.; Omeros Corporation
    Stocks, stock options, or bonds from: Checkpoint Therapeutics, Inc.; Verrica Pharmaceuticals, Inc.
    Other – Independent Contractor: NTC Consulting

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Chii Shyang Fong, PhD, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Evolving Best Practices for Managing AL Amyloidosis: Sharing Perspectives

Authors: Giovanni Palladini, MD, PhD​; Marianna Fontana, MD, PhD; Efstathios Kastritis, MD; Nelson Leung, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 2/1/2022

Valid for credit through: 2/1/2023

processing....

Educational Impact Challenge

The goal of this activity is to improve physicians' understanding of amyloid light chain (AL) amyloidosis and their ability to optimally care for these patients as part of the multidisciplinary team.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print